ImmunoScience, Inc. Email Format
BiotechnologyUnited States11-50 Employees
ImmunoScience, Inc. is a United States-based biotechnology research and development company focused on HIV diagnosis and treatment. Contre Vir is described as a therapeutic vaccine intended to treat HIV infection and AIDS. In pre-clinical studies and early pilot clinical trials, Contre Vir has shown a high level of success, according to the company. The company notes that further studies are being planned in several countries with strong interest. ImmunoScience holds patents for Contre Vir worldwide, and Phase I trials are anticipated in the near term. Preparatory work for these trials has already begun in the United States, Belgium, Ghana, and Uganda.